Advertisement

Archives of Gynecology and Obstetrics

, Volume 296, Issue 6, pp 1229–1234 | Cite as

Diagnosis and treatment of iron-deficiency anaemia in pregnancy and postpartum

  • C. Breymann
  • C. Honegger
  • I. Hösli
  • D. SurbekEmail author
Guidelines and Position Statements

Abstract

Iron deficiency occurs frequently in pregnancy and can be diagnosed by serum ferritin-level measurement (threshold value < 30 μg/L). Screening for iron-deficiency anemia is recommended in every pregnant women, and should be done by serum ferritin-level screening in the first trimester and regular hemoglobin checks at least once per trimester. In the case of iron deficiency with or without anaemia in pregnancy, oral iron therapy should be given as first-line treatment. In the case of severe iron-deficiency anemia, intolerance of oral iron, lack of response to oral iron, or in the case of a clinical need for rapid and efficient treatment of anaemia (e.g., advanced pregnancy), intravenous iron therapy should be administered. In the postpartum period, oral iron therapy should be administered for mild iron-deficiency anemia (haemorrhagic anemia), and intravenous iron therapy for moderately severe-to-severe anemia (Hb < 95 g/L). If there is an indication for intravenous iron therapy in pregnancy or postpartum, iron-containing drugs which have been studied in well-controlled clinical trials in pregnancy and postpartum such as ferric carboxymaltose must be preferred for safety reasons. While anaphylactic reactions are extremely are with non-dextrane products, close surveillance during administration is recommended for all intravenous iron products.

Keywords

Iron deficiency Anemia Pregnancy Postpartum Intravenous 

Notes

Compliance with ethical standards

Funding

This study was funded by the Swiss Society of Gynecology and Obstetrics (SSGO).

Conflict of interest

C. Breymann has received speaker and workshop honorarium, and clinical study support from Vifor Inc. C. Honegger declares that he has no conflict of interest. I. Hösli has received speaker honorarium from Vifor Inc. D. Surbek has received speaker honorarium and an unrestricted grant for a investigator-initiated study from Vifor Inc.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

This expert recommendation has been reviewed by the members of the Quality assurance committee of the SSGO. The Quality Assurance Committee of gynécologie suisse/SGGO (Swiss Society of Obstetrics and Gynaecology) compiles guidelines and expert letters with utmost care. However, the Quality Assurance Committee of gynécologie suisse/SGGG accepts no responsibility for the correctness and completeness of the content. The manufacturer’s instructions must be observed at all times, in particular the dosage instructions. To the Committee’s best knowledge, guidelines and expert letters correspond to the latest scientific insights at the time of publication. Users must take intervening changes into account.

References

  1. 1.
    WHO Global Database. Worldwide prevalence of anemia 1993–2005; 2008Google Scholar
  2. 2.
    Bencaiova G, Breymann C (2014) Mild anemia and pregnancy outcome in a Swiss collective. J Pregnancy 2014:307535CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Hercberg S, Preziosi P, Galan P (2001) Iron deficiency in Europe. Public Health Nutr 4:537–545CrossRefPubMedGoogle Scholar
  4. 4.
    Allen LH (1997) Pregnancy and iron deficiency: unresolved issues. Nutr Rev 55(4):91–101CrossRefPubMedGoogle Scholar
  5. 5.
    Breymann C (2015) Anemia and iron deficiency anemia in gynecology and obstetrics, vol 1. BremenGoogle Scholar
  6. 6.
    Murray-Kolb L (2012) Maternal mortality, child mortality, perinatal mortality, child cognition, and estimates of prevalence of anemia due to iron deficiency. CHERGGoogle Scholar
  7. 7.
    Rondo P, Tomkins A (1999) Maternal iron status and intrauterine growth retardation. Trans RS Trop Med 93:423–426CrossRefGoogle Scholar
  8. 8.
    Gibson RS (1990) Assessment of iron status. Principles of nutritional assessment. Oxford University Press, Oxford, pp 349–376Google Scholar
  9. 9.
    Milman N, Agger A, Nielson O (1991) Iron supplementation during pregnancy. Dan Med Bull 38:471–476PubMedGoogle Scholar
  10. 10.
    Milman N, Graudal N, Agger A (1995) Iron status markers during pregnancy: no relationship between levels at the beginning of the second trimester, prior delivery and post partum. J Int Med 237:261–267CrossRefGoogle Scholar
  11. 11.
    Krafft A, Breymann C (2004) Haemoglobinopathy in pregnancy: diagnosis and treatment. Curr Med Chem 11(21):2903–2909CrossRefPubMedGoogle Scholar
  12. 12.
    Breymann C, Bian XM, Blanco-Capito LR, Chong C, Mahmud G, Rehman R (2011) Expert recommendations for the diagnosis and treatment of iron-deficiency anemia during pregnancy and the postpartum period in the Asia-Pacific region. J Perinat Med 39(2):113–121CrossRefPubMedGoogle Scholar
  13. 13.
    Breymann C, N NM, Mezzacasa A, Bernard R, Dudenhausen J, investigators F-A (2016) Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). J Perinat Med (epub ahead of print) Google Scholar
  14. 14.
    Christoph P, Schuller C, Studer H, Irion O, Tejada BD, Surbek D (2012) Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. J Perinat Med 13(40):469–474Google Scholar
  15. 15.
    Froessler B, Cocchiaro C, Saadat-Gilani K, Hodyl N, Dekker G (2013) Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial. J Matern Fetal Neonatal Med 26(7):654–659CrossRefPubMedGoogle Scholar
  16. 16.
    Froessler B, Collingwood J, Hodyl NA, Dekker G (2014) Intravenous ferric carboxymaltose for anaemia in pregnancy. BMC Pregnancy Childbirth 14:115CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Gupta A, Manaktala U, Rathore AM (2014) A randomised controlled trial to compare intravenous iron sucrose and oral iron in treatment of iron deficiency anemia in pregnancy. Indian J Hematol Blood Transfus 30(2):120–125CrossRefPubMedGoogle Scholar
  18. 18.
    Breymann C, Gliga F, Bejenariu C, Strizhova N (2008) Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 101(1):67–73CrossRefPubMedGoogle Scholar
  19. 19.
    Rathod S, Samal SK, Mahapatra PC, Samal S (2015) Ferric carboxymaltose: a revolution in the treatment of postpartum anemia in Indian women. Int J Appl Basic Med Res 5(1):25–30CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Gravier A (1999) Avoiding postpartum transfusions: the utility of intravenous iron supplementation (translation). J Gynecol Obstet Biol Reprod 28:77–78Google Scholar
  21. 21.
    Muñoz M, Breymann C, García-Erce J, Gómez-Ramírez S, Comin J, Bisbe E (2008) Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. Vox San 94(3):172–183CrossRefGoogle Scholar
  22. 22.
    Gupta A, Rathore AM, Manaktala U, Gupta A, Gupta S (2015) Role of intravenous iron sucrose in correction of anemia in antenatal women with advanced pregnancy. Indian J Hematol Blood Transfus 31(2):251–254CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • C. Breymann
    • 1
  • C. Honegger
    • 2
  • I. Hösli
    • 3
  • D. Surbek
    • 4
    Email author
  1. 1.ZurichSwitzerland
  2. 2.ZugSwitzerland
  3. 3.BaselSwitzerland
  4. 4.Department of Obstetrics and Gynecology, University HospitalUniversity of BernBernSwitzerland

Personalised recommendations